Typhoid final year mbbs student for university examinations
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have all the content needed for a comprehensive final year MBBS examination answer. Let me compose it.
Typhoid Fever (Enteric Fever) - Final Year MBBS Comprehensive Notes
1. Definition
Typhoid (enteric) fever is a systemic febrile illness caused by Salmonella enterica serotype Typhi (S. Typhi) or Paratyphi (A, B, C), characterized by prolonged continuous fever, relative bradycardia, splenomegaly, rose spots, and involvement of the lymphoid tissue of the gut (Peyer's patches). The term "enteric fever" covers both typhoid and paratyphoid fevers.
2. Etiology & Microbiology
| Feature | Detail |
|---|---|
| Organism | S. enterica serovar Typhi (main); Paratyphi A, B, C |
| Gram stain | Gram-negative bacillus (Enterobacteriaceae) |
| Reservoir | Humans ONLY (no animal reservoir) |
| Antigens | O (somatic), H (flagellar), Vi (virulence/capsular) |
| Phage types | >80 phage types; used for epidemiological tracing |
| Survival | Killed by drying, pasteurization, and common disinfectants |
The Vi antigen is important: it inhibits phagocytosis and complement activation, aiding immune evasion.
3. Epidemiology
- Global burden: 9-21 million cases of typhoid fever annually; 110,000-280,000 deaths/year (Harrison's, 22nd ed.)
- India: Endemic; 2.30 million cases in 2018; highest from Uttar Pradesh
- High-risk areas: Indian subcontinent (India, Pakistan, Bangladesh, Nepal), Southeast Asia, Africa, Latin America
- Age group most affected: 5-19 years (highest incidence); incidence falls after age 20 due to acquired immunity
- Sex: More cases in males (higher exposure); but carrier rate higher in females
- Risk factors: Contaminated water/food, street food, poor sanitation, lack of hand washing, prior H. pylori infection (reduced gastric acidity)
4. Pathogenesis (Key for Exams)
- Ingestion - organisms ingested with contaminated food/water (infective dose: 10^5-10^9 organisms)
- Gastric acid barrier - partially overcome; low gastric acidity increases susceptibility
- Small intestine - organisms penetrate the mucosa via M cells overlying Peyer's patches in the terminal ileum
- Peyer's patches - organisms taken up by mononuclear cells; Peyer's patches enlarge into plateau-like elevations (up to 8 cm); mucosal shedding creates oval ulcers along the long axis of the ileum
- Primary bacteremia - organisms enter mesenteric lymph nodes, thoracic duct, and bloodstream (1st bacteremia - usually asymptomatic; corresponds to incubation period)
- Reticuloendothelial system - organisms multiply in macrophages of liver (Kupffer cells), spleen, bone marrow, and lymph nodes
- Secondary bacteremia - massive release back into blood → clinical illness begins
- Re-seeding of gut - organisms excreted in bile re-infect the already-sensitized Peyer's patches → inflammatory response → ulceration, risk of perforation and hemorrhage
Key Pathological Features (Robbins):
- Peyer's patch hyperplasia → necrosis → oval ulcers (longitudinal axis of ileum)
- Reactive hyperplasia of draining lymph nodes
- Typhoid nodules - small foci of parenchymal necrosis with macrophage aggregates in liver, bone marrow, and lymph nodes
- Spleen: red pulp expansion due to phagocyte hyperplasia
- Gallbladder colonization - associated with gallstones and chronic carrier state
Cell-mediated immunity is the primary defence (S. typhi is an intracellular organism).
5. Clinical Features
Incubation Period
- Mean 10-14 days (range 5-21 days)
Classical Stepladder Pattern of Fever (Wunderlich curve)
Week 1: Fever rises in a stepladder fashion, reaching 39-40°C; headache, malaise, dry cough, constipation (in adults), relative bradycardia
Week 2: Fever becomes sustained/continuous (40-40.5°C); "pea-soup" diarrhea may appear; splenomegaly; rose spots; toxic look
Week 3: Complications may occur (perforation, hemorrhage); typhoid state (apathy, disorientation)
Week 4: Defervescence if untreated and uncomplicated
Cardinal Signs
| Sign | Detail |
|---|---|
| Fever | Prolonged, high-grade (38.8-40.5°C); present in >75% at presentation |
| Relative bradycardia | Faget's sign - pulse-temperature dissociation; seen at peak of fever |
| Rose spots | Faint salmon-colored, blanching maculopapular rash on trunk/chest; seen in ~30%; 2-5 days duration; S. Typhi can be cultured from biopsy |
| Splenomegaly | Soft, tender; 3-6% on initial presentation but more common later |
| Coated tongue | Furring of tongue (51-56%) |
Common Symptoms (Harrison's):
- Headache (80%), chills (35-45%), cough (30%), anorexia (55%), abdominal pain (30-40%), nausea, vomiting, diarrhea (22-28%), constipation (13-16%)
6. Complications
Intestinal (Most Important - Bailey & Love):
- Intestinal hemorrhage - from ulceration of Peyer's patches (Week 2-3); presents with sudden drop in temperature, pulse rate rise, melena
- Intestinal perforation - most feared; terminal ileum; presents as acute abdomen; highest mortality
Extraintestinal:
| System | Complications |
|---|---|
| Hepatobiliary | Hepatitis, cholecystitis, chronic carrier state |
| Cardiovascular | Myocarditis, endocarditis |
| Pulmonary | Pneumonia, empyema |
| Neurological | Encephalopathy, meningitis, seizures, Guillain-Barre syndrome |
| Hematological | DIC, hemolytic anemia |
| Renal | Glomerulonephritis |
| Other | Osteomyelitis, arthritis (especially in sickle cell disease) |
7. Diagnosis
A. Bacteriological (Gold Standard)
| Specimen | Timing | Yield |
|---|---|---|
| Blood culture | Week 1-2 (during bacteremia) | 90% positive during febrile phase; best in Week 1 |
| Bone marrow culture | Any time; even after antibiotics | Highest yield (~90%); gold standard even after treatment |
| Stool culture | Week 2-3 | Useful; organisms re-shed via bile |
| Urine culture | Week 3 | Lower yield |
| Rose spot biopsy | During rash | Can culture S. Typhi |
Bone marrow culture is the most sensitive - remains positive even after antibiotics have been started.
B. Widal Test (Serological)
- Measures agglutinating antibodies against O and H antigens
- O antibodies: Appear Day 6-8; indicate active/recent infection; rise in 4-fold titre diagnostic
- H antibodies: Appear Day 10-12; remain elevated longer; indicate past infection or vaccination
- Vi antibodies: Used to detect chronic carriers
- Diagnostic titre: O ≥ 1:160 (in non-endemic area) or a 4-fold rise in paired sera
- Limitations:
- False positives: malaria, typhus, bacteremia, cirrhosis, other Enterobacteriaceae cross-reactions
- False negatives: early antibiotic therapy (blunts antibody response), up to 30% of culture-proven cases
- Prior vaccination raises H titres (not diagnostic of active disease)
C. Newer Rapid Tests
| Test | Principle | Note |
|---|---|---|
| Typhidot® | Detects IgM and IgG against 50 kDa S. typhi antigen | Takes 3 hours |
| Typhidot-M® | Detects IgM only (more specific for acute disease) | More specific than Typhidot |
| Tubex® (IDL) | Detects IgM anti-O9 antibodies | Results in minutes |
| Dipstick test | S. typhi-specific IgM against LPS | Developed in Netherlands |
D. Other Lab Findings
- Leukopenia (characteristic) - low or normal WBC despite high fever
- Relative lymphocytosis
- Elevated liver enzymes (transaminitis)
- Thrombocytopenia
- Normochromic normocytic anemia
8. Treatment
Drug of Choice
Fluoroquinolones (Ciprofloxacin, Ofloxacin) are classically the drug of choice - rapid bactericidal action, good tissue penetration, inexpensive.
- Ciprofloxacin 500 mg BD x 7-10 days (uncomplicated)
- Ofloxacin 400 mg BD x 7-10 days
However - Drug Resistance is a Critical Issue:
| Resistance Type | Definition | Treatment |
|---|---|---|
| MDR S. Typhi | Resistant to chloramphenicol, ampicillin, AND cotrimoxazole (all 3 first-line) | Fluoroquinolones or ceftriaxone |
| DSC S. Typhi | Decreased susceptibility to ciprofloxacin (MIC ≥0.125 μg/mL) | Ceftriaxone or azithromycin |
| XDR S. Typhi | MDR + resistant to fluoroquinolones AND 3rd-gen cephalosporins | Azithromycin or carbapenems |
XDR S. Typhi emerged in 2016 in Sindh, Pakistan - now a major public health crisis.
Treatment Options by Scenario:
| Scenario | Drug |
|---|---|
| Uncomplicated, sensitive | Ciprofloxacin 500 mg BD x 7-10 days |
| MDR (not DSC) | Ceftriaxone 2g IV OD x 10-14 days OR azithromycin |
| DSC/XDR | Azithromycin 1g OD x 5-7 days; carbapenems for severe XDR |
| High quinolone resistance area | Azithromycin 1g OD x 5 days |
| Severe/complicated | Ceftriaxone IV; dexamethasone for severe typhoid with altered consciousness |
Historical first-line drugs (now largely replaced due to MDR):
- Chloramphenicol (first effective drug; 1948)
- Ampicillin
- Co-trimoxazole (TMP-SMX)
Steroids
- Dexamethasone (3 mg/kg loading, then 1 mg/kg 8-hourly x 8 doses) for severe typhoid with altered mental status or shock - shown to reduce mortality.
Chronic Carrier Treatment
- Ciprofloxacin 750 mg BD x 28 days (or norfloxacin)
- Cholecystectomy if gallstones present with chronic carrier state
9. Carriers
| Type | Duration of Excretion |
|---|---|
| Incubatory carrier | Excretes during incubation period |
| Convalescent carrier | Excretes for 6-8 weeks post-illness |
| Chronic carrier | Excretes >1 year (2-5% of cases) |
- "Typhoid Mary" - the classic chronic carrier who caused >1300 cases
- Organisms persist in gallbladder and biliary tract
- Chronic urinary carrier state associated with urinary tract abnormality
- Faecal carriers more common than urinary carriers
10. Prevention & Control (Park's PSM)
Three lines of defence:
- Control of reservoir
- Control of sanitation (weakest link in transmission - most amenable to control)
- Immunization
A. Control of Reservoir
- Early diagnosis and notification
- Isolation until 3 bacteriologically negative stool/urine cultures on separate days
- Treatment of cases and carriers
- Disinfection of excreta and environment
B. Sanitation
- Safe water supply (chlorination, boiling)
- Proper sewage disposal
- Food hygiene - pasteurization of milk, food inspection
- Fly control
- Hand washing
C. Vaccines
| Vaccine | Type | Schedule | Efficacy | Duration |
|---|---|---|---|---|
| Ty21a (Vivotif®) | Live attenuated oral (S. Typhi Ty21a strain) | 4 oral capsules on alternate days | ~70% | 5-7 years |
| Vi polysaccharide (ViPS) | Purified Vi capsular polysaccharide (injectable) | Single dose SC/IM | ~70-75% | 3 years; revaccinate |
| Typhoid Conjugate Vaccine (TCV - Typbar-TCV®) | Vi conjugated to tetanus toxoid (injectable) | Single dose; from 6 months of age | >80% | Longer (years); T-cell dependent |
TCV is recommended by WHO for children in endemic countries from 6 months; also provides immunological memory (unlike plain ViPS which is T-cell independent and not effective below 2 years).
11. High-Yield Exam Points (Summary)
| Point | Fact |
|---|---|
| Only reservoir | Humans (no animal reservoir) |
| M/C site of ulceration | Terminal ileum; ulcers along long axis (longitudinal) |
| Most sensitive culture | Bone marrow culture (even after antibiotics) |
| Best culture in Week 1 | Blood culture |
| Widal: O antibody appears | Day 6-8 |
| Widal: H antibody appears | Day 10-12 |
| Relative bradycardia | Faget's sign |
| M/C complication | Intestinal hemorrhage (most feared = perforation) |
| Chronic carrier site | Gallbladder / biliary tract |
| "Typhoid Mary" | Classic chronic carrier |
| Drug of choice | Fluoroquinolones (but resistance rising) |
| XDR typhoid emerged | Pakistan (Sindh), 2016 |
| Vaccine for infants (<2 yr) | Only TCV (Vi conjugate); plain ViPS ineffective |
| Cell-mediated immunity | Primary defence (intracellular organism) |
| Leukopenia | Classic hematological finding despite high fever |
| Steroid indication | Severe typhoid with encephalopathy/shock (dexamethasone) |
Sources: Harrison's Principles of Internal Medicine 22nd Ed. (2025) | Robbins & Kumar Basic Pathology | Park's Textbook of Preventive and Social Medicine | Sleisenger & Fordtran's GI and Liver Disease | Bailey & Love's Short Practice of Surgery 28th Ed.
This is a shared conversation. Sign in to Orris to start your own chat.